NMN Knowledge Update
In 2023, a research team led by David Sinclair at Harvard Medical School published a significant finding in The Journal of Clinical Endocrinology & Metabolism. The study primarily investigated the effects of NMN (Nicotinamide Mononucleotide) on the weight, cholesterol, and blood pressure of overweight or obese adults.
What happened to the weight of middle-aged and elderly individuals who took 2000 mg of NMN daily for 28 days?
The study recruited 30 overweight or obese adults over the age of 45. Participants were randomly divided into two groups: one group took NMN twice daily (1000 mg each time), and the other group took a placebo, for a duration of 28 days. During the study period, participants’ weight, blood cholesterol levels, and blood pressure were regularly monitored.
Weight Change:
Participants who took NMN lost over 6 pounds (approximately 2.72 kilograms) compared to those who did not take NMN, indicating that NMN supplementation can promote metabolic function and help with weight loss.
Cholesterol Levels:
NMN significantly lowered total blood cholesterol levels, including low-density lipoprotein (LDL) cholesterol, which is closely associated with cholesterol buildup in the arteries. This finding supports the potential cardiovascular benefits of NMN.
Blood Pressure Changes:
The study also found that NMN specifically reduced diastolic blood pressure (a key factor in hypertension) without significantly affecting systolic blood pressure. This suggests that NMN supplementation may be a potential strategy for alleviating hypertension in overweight and obese adults.
Overall, this study provides strong clinical evidence for the application of NMN in weight management and cardiovascular health maintenance.